Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 92

Results For "therapy"

1501 News Found

Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
News | January 06, 2023

Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment

Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


BDR Pharmaceutical launches the first generic to treat Prostate cancer in India
News | January 04, 2023

BDR Pharmaceutical launches the first generic to treat Prostate cancer in India

BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.


Polysciences announces new bioprocessing brand ‘Kyfora Bio’
News | January 03, 2023

Polysciences announces new bioprocessing brand ‘Kyfora Bio’

Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.


Alniche Life Sciences launches #GutHealthAwareness campaign
Healthcare | December 31, 2022

Alniche Life Sciences launches #GutHealthAwareness campaign

Having a healthy gut is key as it permits the body to build a stronger immune system


USFDA grants appeal for Ardelyx's XPHOZAH
Drug Approval | December 31, 2022

USFDA grants appeal for Ardelyx's XPHOZAH

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism


InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
Drug Approval | December 31, 2022

InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong

Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency


Cipla EU to invest € 15 million in Ethris
News | December 30, 2022

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies


Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
News | December 28, 2022

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze


NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
News | December 27, 2022

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.